Mayo Clinic Mayo Myeloma SPORE Renewal 2025
Official title: Mayo Clinic Multiple Myeloma SPORE - Renewal 2025
Funded at Mayo Clinic Arizona · NIH-11421168 · Data updated 2026-11-12
A Mayo Clinic research program is renewing a translational effort to advance personalized approaches for multiple myeloma that could benefit patients at Mayo sites and beyond.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Arizona NIH-funded |
| Lab location | 1 site (Scottsdale, United States) |
| Project start | September 1, 2015 |
| Project end | August 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $1,879,425 |
| NIH project number | 2P50CA186781-11 |
| Project ID | NIH-11421168 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with multiple myeloma who participate in translational and clinical trials through Mayo Clinic sites.
✕Less likely to help
Patients not enrolled in or eligible for the SPORE translational and clinical trial activities may not directly benefit.
What this research studies
This grant supports a collaborative program across Mayo Clinic sites to move lab discoveries into clinical care for multiple myeloma. It emphasizes teams that combine basic biology, translational science, and patient-focused clinical trials to identify new markers and prognostic tools. The goal is to speed innovations from the lab to the clinic so patients have access to better diagnostics and treatments. The program also includes mechanisms for patient advocates to contribute to research directions and trial development.
Why it matters
Potential benefit: If successful, patients with multiple myeloma could see faster access to validated biomarkers and new therapeutic options.
How similar studies have gone: Previous SPORE projects have identified tumor markers and prognostic indices used in clinical trials and practice.
Where this research is happening
-
Mayo Clinic Arizona
Scottsdale, United States Active
Researchers
- Principal investigator: Bergsagel, Peter Leif — Mayo Clinic Arizona
- Study coordinator: Bergsagel, Peter Leif
Related research
Other NIH-funded projects on the same topics.
-
Integrative study of multiple myeloma genetics and disease biology
A team at Dana-Farber and partners is pursuing a long-term project to understand the genetic and molecular drivers of multiple myeloma and how treatments interact with disease biology.
-
Comparative Modeling to Prevent, Detect Early, and Treat Multiple Myeloma
A research team will build and compare computer models to understand how multiple myeloma develops, can be detected earlier, and treated more effectively.
-
How LDL Affects Multiple Myeloma: New Pathways to Keep Remission
A new grant is studying how cholesterol from LDL particles fuels multiple myeloma and how this interaction influences the tumor environment and immune response, with goals to help patients stay in remission.
-
Therapy-induced senescence and immune activation in multiple myeloma
A study in people with multiple myeloma will explore how treatment-related senescence in cancer cells may stimulate the immune system and affect cancer return after standard frontline therapy.
-
BCMA CAR-T enteritis: understanding immune toxicities in multiple myeloma
A broad study to uncover why some CAR-T cell treatments targeting BCMA cause severe intestinal inflammation in people with multiple myeloma.
-
Understanding Drug-Resistant Multiple Myeloma to Stop Relapse
Researchers are studying why some myeloma cells resist treatment and how to create new therapies to prevent relapse.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.